RxDoctor Payments Data

Gaurang Patel, MD

Internal Medicine · Palm Bay, FLNPI 1366739773

Payments from drug & device makers

$1,486in general payments, 2019–2025

Across 73 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$599
  • Novartis$162
  • Exact Sciences$106
  • Phathom Pharmaceuticals, Inc.$78
  • Pfizer$70
  • Amgen$64
  • plus $407 from 13 others

What the payments were for

  • Food & beverage$1,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,486 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$382,850
Medicare patients
742
Services billed
3,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban500$212,715
OzempicSemaglutide40$60,038
XareltoRivaroxaban107$54,378
JardianceEmpagliflozin41$32,213
JanuviaSitagliptin Phosphate27$30,908
XifaxanRifaximin17$25,797
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,568
FarxigaDapagliflozin Propanediol24$21,348
EntrestoSacubitril/Valsartan33$19,539
MounjaroTirzepatide16$17,237
SantylCollagenase Clostridium Hist.14$15,991
LinzessLinaclotide24$14,387
Repatha SyringeEvolocumab17$12,105
TrulicityDulaglutide14$10,625
Gabapentin438$7,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$70$216,172512 claims
Novo NordiskOzempic$37$60,03840 claims
Johnson & JohnsonXarelto$599$54,378107 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta$16$34,94563 claims
AstraZenecaFarxiga, Lokelma, Brilinta$60$34,54761 claims
MerckJanuvia$15$30,90827 claims
Lilly USA, LLCMounjaro, Trulicity$50$27,86230 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$20$25,79717 claims
NovartisEntresto$162$19,53933 claims
AbbVieLinzess, Namzaric$37$17,96936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Palm Bay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →